Brief: Medicenna Selects Its Lead Immuno-Oncology Clinical Candidate, Mdna19, From Its Il-2 Superkine Platform

Medicenna Therapeutics

31/07/2019 12:22

Medicenna Therapeutics Corp  MDNA.TO :
    * MEDICENNA SELECTS ITS LEAD IMMUNO-ONCOLOGY CLINICAL
CANDIDATE,
MDNA19, FROM ITS IL-2 SUPERKINE PLATFORM
    * MEDICENNA THERAPEUTICS CORP - MDNA19 DEMONSTRATES ROBUST
EFFICACY AND SAFETY WITH OR WITHOUT CHECKPOINT INHIBITORS IN
PRECLINICAL MODELS
    * MEDICENNA THERAPEUTICS CORP - CLINICAL STUDIES EXPECTED TO
COMMENCE IN 2020

Source text for Eikon:  ID:nPnc8Fc5pa 
Further company coverage:  MDNA.TO